F-1/A: Nano Labs Ltd Files Amendment No. 1 to Form F-1 Registration Statement for Resale of Class A Ordinary Shares

Nano Labs Ltd files an amendment to its Form F-1 registration statement concerning the proposed resale of 6,521,737 Class A ordinary shares issuable upon the exercise of warrants.

Summary

• Nano Labs Ltd has filed Amendment No. 1 to its Form F-1 registration statement with the SEC.
• The amendment pertains to the proposed resale or other disposition of 6,521,737 Class A ordinary shares, which are issuable upon the exercise of warrants by the selling shareholders.
• These warrants were acquired by the selling shareholders through a securities purchase agreement dated April 11, 2024, in a private placement.
• Nano Labs will not receive any proceeds from the sale of these Class A ordinary shares by the selling shareholders, but will receive proceeds from the exercise of the Warrants.
• The selling shareholders may offer these shares from time to time through public or private transactions at prevailing market prices or negotiated prices.
• The company's Class A ordinary shares are listed on the NASDAQ Global Market under the symbol NA.
• The last reported sale price on April 26, 2024, was US$0.4755 per share.
• The document addresses risks related to conducting business in China, including potential delisting under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB cannot inspect the company's auditors.
• The document also mentions the PRC government's oversight and potential intervention in the company's operations.
• The company is an emerging growth company and a foreign private issuer, which allows it certain exemptions from U.S. securities rules and regulations.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focusing on regulatory compliance and the mechanics of a share resale. The inclusion of risk factors tempers any positive outlook.

Positives

• The company has the potential to receive proceeds if the warrants are exercised.
• The company is an emerging growth company, allowing it to comply with reduced public company reporting requirements.

Negatives

• Nano Labs will not receive any proceeds from the sale of Class A ordinary shares by the selling shareholders.
• The company faces risks related to operating in China, including potential delisting under the HFCAA and government intervention.
• The company's Class A ordinary shares could be delisted if the PCAOB is unable to inspect auditors located in China for two consecutive years.

Risks

• Delisting of Class A ordinary shares under the HFCAA if the PCAOB cannot inspect auditors in China.
• PRC government intervention in the company's operations.
• Uncertainties in the enforcement of and changes in laws and regulations in China.
• Recent regulatory developments in China may subject the company to additional regulatory review.
• The trading price of the Class A ordinary shares is likely to be volatile, which could result in substantial losses to investors.

Future Outlook

The selling shareholders may offer and sell the ordinary shares from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices.

Industry Context

This announcement reflects the ongoing complexities and regulatory scrutiny faced by China-based companies listed on U.S. exchanges, particularly in sectors involving data and technology. The HFCAA and related concerns about audit access continue to be a significant factor for these companies.

Comparison to Industry Standards

• It is difficult to compare Nano Labs' situation directly to industry standards without specific financial benchmarks from comparable companies.
• However, the risks highlighted regarding PCAOB compliance and potential delisting are common concerns for other China-based companies listed in the U.S., such as Alibaba, Baidu, and JD.com.
• These companies have also taken measures to address these risks, including exploring secondary listings in Hong Kong and improving transparency.
• The potential for PRC government intervention is also a shared concern among these companies.

Stakeholder Impact

• Shareholders may experience volatility in the share price due to potential sales by selling shareholders.
• The company's ability to raise capital in the future could be affected by regulatory actions and market perceptions.
• Employees may be affected by changes in the company's financial condition and regulatory compliance.

Next Steps

• The selling shareholders will proceed with the potential resale of Class A ordinary shares.
• Nano Labs will monitor compliance with PCAOB and SEC regulations to maintain its NASDAQ listing.
• The company will continue to navigate the evolving regulatory landscape in China.

Key Dates

Keywords

Class A ordinary shares, warrants, HFCAA, PCAOB, delisting, China, resale, Nano Labs